General Experimental
All reagents were purchased from Sigma-Aldrich or AlfaAesar and were used as received without further purification. Where described below petrol refers to petrol (b.p. 40-60 °C). All reactions were monitored by thin-layer chromatography (TLC) on pre-coated SIL G/UV254 silica gel plates (254 m) purchased from VWR. Flash column chromatography was carried out with Kiesegel 60M 0.04/0.063 mm (200-400 mesh) silica gel. 1 H and 13 C NMR spectra were recorded at ambient temperature on a Bruker Avance 600 instrument operating at a frequency of 600 MHz for 1 H and 150 MHz for 13 C in a deuterated solvent as described below. The chemical shifts () for 1 H and 13 C are quoted relative to residual signals of the solvent on the ppm scale. 1 
H NMR peaks are reported as singlet (s), doublet (d), triplet (t), quartet (q), quintet (quintet), broad (br) or multiplet (m). Coupling constants (J values) are reported in
Hertz (Hz) and are H-H coupling constants unless otherwise stated. Signal multiplicities in 13 C NMR were determined using the distortionless enhancement by phase transfer (DEPT) spectral editing technique. Infrared spectra were obtained on a Perkin Elmer Spectrum 100 FTIR Spectrometer operating in ATR mode with frequencies given in reciprocal centimetres (cm -1 ). Melting points were measured with a Gallenkamp apparatus and are uncorrected. Mass spectra were obtained on a VG70-SE mass spectrometer. Optical rotations were measured using a Perkin Elmer 343 polarimeter.
LC-MS was performed on protein samples using a Thermo Scientific uPLC connected to MSQ Plus Single Quad Detector (SQD). Column: Hypersil Gold C4, 1.9 µm 2.1 x 50 mm. Wavelength: 254 nm. Mobile Phase: 99:1 Water:MeCN (0.1% formic acid) to 1:9 Water: MeCN (0.1% formic acid) gradient over 4 min. Flow Rate: 0.3 mL/min. MS Mode: ES + . Scan Range: m/z = 500-2000. Scan time: 1.5 s. Data obtained in continuum mode. The electrospray source of the MS was operated with a capillary voltage of 3.5 kV and a cone voltage of 50 V. Nitrogen was used as the nebulizer and desolvation gas at a total flow of 600 L/h. Ion series were generated by integration of the total ion chromatogram (TIC) over the 3.5-5.0 min range. Total mass spectra for protein samples were reconstructed from the ion series using the preinstalled ProMass software.
3,4-Dibromo-furan-2,5-dione 1 A mixture of maleic anhydride (1.50 g, 15.3 mmol), AlCl 3 (28 mg, 0.21 mmol) and Br 2 (1.57 mL, 4.89 g, 30.6 mmol) was heated at 160 ºC in a sealed ampoule for 20 h. After this time, the reaction mixture was allowed to cool to room temperature, and diluted with EtOAc (25 mL). The reaction mixture was then filtered and the solid washed thoroughly with EtOAc (3 × 25 mL). The filtrate was then concentrated in vacuo to afford 3,4-dibromo-furan-2,5-dione as a yellow solid (3.25 
3,4-Bis-ethylsulfanyl-1-phenyl-pyrrole-2,5-dione 2
To a solution of 3,4-dibromo-1-phenyl-pyrrole-2,5-dione 1 (237 mg, 0.72 mmol) in CH 2 Cl 2 (30 mL) was added ethanethiol (0.11 mL, 1.50 mmol) and NEt 3 (0.21 mL, 1.50 mmol), and the reaction mixture stirred at room temperature for 15 min. After this time, the solvents were removed in vacuo and the crude residue purified by flash column chromatography (5% EtOAc/petrol) to afford 3,4-bis-ethylsulfanyl-1-phenyl-pyrrole-2,5-dione 2 as a yellow oil (195 To a solution of 3,4-dibromo-furan-2,5-dione (1.0 g, 3.9 mmol) and N-methylmorpholine (0.43 mL, 3.9 mmol) in THF (35 mL) was added methyl chloroformate (0.30 mL, 3.9 mmol) and the reaction mixture stirred at room temperature for 20 min. After this time, CH 2 Cl 2 (40 mL) was added, the organic phase washed with H 2 O (3 × 40 mL), dried (MgSO 4 ) and the solvent removed in vacuo to afford 3,4-dibromo-2,5-dioxo-2,5-dihydro-pyrrole-1-carboxylic acid methyl ester 5 as a pink powder ( 
Phenyl-carbamic acid 4-(3,4-bis-ethylsulfanyl-2,5-dioxo-2,5-dihydro-pyrrol-1-yl)-benzyl ester 7
To a solution of 3,4-bis-ethylsulfanyl-1-(4-hydroxymethyl-phenyl)-pyrrole-2,5-dione (100 mg, 0.309 mmol) in CH 2 Cl 2 (14 mL) was added phenylisocyanate (0.035 mL, 0.322 mmol) and NEt 3 (0.091 mL, 0.653 mmol), and the reaction mixture stirred at room temperature for 2 days. After this time, the reaction mixture was concentrated in vacuo and the crude residue purified by flash column chromatography (20% EtOAc/petrol) to afford phenyl-carbamic acid 4-(3, 
3,4-Bis-ethylsulfanyl-furan-2,5-dione 4 and aniline
To a solution of phenyl-carbamic acid 4-(3,4-bis-ethylsulfanyl-2,5-dioxo-2,5-dihydro-pyrrol-1-yl)-benzyl ester 7 (19.5 mg, 0.044 mmol) in a 1:1 mixture of CD 3 OD:D 2 O (0.8 mL:0.8 mL) was added LiOH.H 2 O (102 mg, 2.44 mmol) and the reaction mixture stirred at room temperature for 2 h. After this time, 2M HCl was added and the reaction mixture acidified to pH 4. Then, 3,4-bis-ethylsulfanyl-furan-2,5-dione 4 was extracted from the reaction mixture into EtOAc (3 × 20 mL), washed with sat. NaCl, dried (MgSO 4 ), filtered and the solvents removed in vacuo to afford 3,4-bis-ethylsulfanyl-furan-2,5-dione 4 as an oil (9.6 mg, 0.044 mmol, >99%). Data matched that described above.
The pH 4, aqueous solution was neutralised by addition of 1M NaOH. Then, the organic materials were extracted into CHCl 3 (3 × 5 mL), dried (MgSO 4 ), filtered and the solvent was removed in vacuo. The crude residue was purified by flash column chromatography (10% EtOAc/petrol) to afford aniline as an oil (3.9 mg, 0.042 mmol, 95%). 
1-(4-Hydroxymethyl-phenyl)-3,4-bis-phenylsulfanyl-pyrrole-2,5-dione 8
To a solution of 3,4-dibromo-1-(4-hydroxymethyl-phenyl)-pyrrole-2,5-dione 6 (139 mg, 0.385 mmol) in CH 2 Cl 2 (18 mL) was added NEt 3 (0.145 mL, 1.04 mmol) and phenylthiol (0.08 mL, 0.809 mmol), and the reaction mixture stirred at room temperature for 30 min. After this time, the reaction mixture was concentrated in vacuo and the crude residue purified by flash column chromatography (20% EtOAc/petrol) to afford 1-(4-hydroxymethyl-phenyl)- 
Carbonic acid 4-(2,5-dioxo-3,4-bis-phenylsulfanyl-2,5-dihydro-pyrrol-1-yl)-benzyl ester 4-nitro-phenyl ester 9
To a solution of 1-(4-hydroxymethyl-phenyl)-3,4-bis-phenylsulfanyl-pyrrole-2,5-dione 8 (30 mg, 0.071 mmol) in CH 2 Cl 2 (2 mL) was added 4-nitrophenylchloroformate (17 mg, 0.085 mmol) and pyridine (0.007 mL, 0.085 mmol, and the reaction mixture was stirred at room temperature for 24 h. After this time, CH 2 Cl 2 (10 mL) and 10% aqueous citric acid (10 mL) were added, the organic phase washed with H 2 O (10 mL) and sat. NaCl (10 mL), dried (MgSO 4 ), filtered and the solvent removed in vacuo. The resultant crude residue was purified by flash column chromatography (20% EtOAc/petrol) to afford carbonic acid 4-(2,5-dioxo-3,4-bis-phenylsulfanyl-2,5-dihydro-pyrrol-1-yl)-benzyl ester 4-nitro-phenyl ester 9 as an oil (30 mg, 0.051 mmol, 72%): To a solution of carbonic acid 4-(2,5-dioxo-3,4-bis-phenylsulfanyl-2,5-dihydro-pyrrol-1-yl)-benzyl ester 4-nitro-phenyl ester 9 (9.8 mg, 0.017 mmol) and DOX·HCl (10 mg, 0.018 mmol) in NMP (0.30 mL) was added NEt 3 (2.5 µL, 0.018 mmol), and the reaction mixture stirred at room temperature for 3 days. After this time, the reaction mixture was diluted with 10% i-propanol/EtOAc, washed with H 2 O (10 mL) and sat. NaCl (10 mL), dried (MgSO 4 ), filtered and the solvent removed in vacuo. The crude residue was purified by flash column chromatography (2% MeOH/CH 2 Cl 2 ) to afford {3-Hydrohxy-2-methyl-6-[3,5,12-trihydroxy-3- .
Preparation of trastuzumab Fab fragment (11) using sequential digests with pepsin and papain
Immobilized pepsin (0.15 mL) was washed with digestion buffer (20 mM sodium acetate trihydrate, pH 3.1) four times and trastuzumab (0.5 mL, 6.41 mg/mL in digestion buffer) was added. The mixture was incubated for 5 h at 37 ºC whilst shaking (1100 rpm). The resin was separated from the digest using a filter column, and washed with digest buffer (50 mM phosphate, 1 mM EDTA, 150 mM NaCl, pH 6.8) three times. The digest was combined with the washes and the volume adjusted to 0.5 mL. The sample was analysed by LCMS and revealed formation of trastuzumab-F(ab') 2 , LCMS observed mass: 97303. After this, papain (1 mL, 0.25 mg/mL) was activated with 10 mM DTT (in digest buffer: 50 mM phosphate, 1 mM EDTA, 150 mM NaCl, pH 6.8) under an argon atmosphere whilst shaking (1100 rpm) for 1 h at 25 ºC in the dark. The resin was washed with digest buffer (without DTT) four times and the 0.5 mL of Herceptin-F(ab') 2 added. The mixture was incubated for 16 h at 37 ºC whilst shaking (1100 rpm) in the dark. Then the resin was separated from the digest using a filter column, and washed with PBS (pH 7.0) three times. The digest was combined with the washes and the buffer was exchanged completely for PBS (pH 7.4) using diafiltration columns (10 KDa MWCO) and the volume adjusted to 0.4 mL. 
Preparation of processed trastuzumab Fab
A solution of Fab fragment 11 (50 L, 1.72 mg/mL, 25 mM sodium borate, 25 mM NaCl, 1 mM EDTA, pH 8.0) was incubated for 1.5 h at 37 °C. After this time, to the solution were added MeCN (13 L, 20% v/v) and DMF (6.5 L, 10% v/v) and the reaction maintained at 37 °C for 1 h. Next, the reaction mixture was buffer exchanged into PBS (pH 7.4, final volume: 50 µL), and the solution incubated for 20 h at 37 °C. After this time, the reaction mixture was analysed by LCMS to reveal processed Fab (expected mass: 47644 Da, observed mass: 47650 Da). 
Protocol for ELISA
96-Well plates were coated overnight at 4 ºC with HER2 (0.25 μg/mL); PBS was used as negative control. HER2 was removed; the wells washed with PBS and blocked with 200 μL of 1% BSA solution for 2 h at room temperature. After washing with PBS, the serially diluted test samples (30 nM, 10 nM, 3.33 nM, 1.11 nM, 0.37 nM, 0.12 nM) were added and incubated for 1 h at room temperature. The wells were washed twice with PBS-T (PBS, 0.1% Tween-20) and once with PBS, and anti-human IgG, Fab-specific-HRP antibody (Sigma-Aldrich) was incubated for 1 h at room temperature to detect the bound test sample. The plates were washed again and 100 μL of 0.5 mg/mL o-phenylenediamine hydrochloride (Sigma-Aldrich) in a phosphate-citrate buffer with sodium perborate were added as substrate. Once colour was visible, the reaction was stopped by acidifying with 50 μL of 4M HCl. Absorbance was immediately measured at 490 nm. ELISA assays were conducted for trastuzumab Fab 11, processed Fab and Fab ADC 13. 
